Metabolic & weight · Peptide
Retatrutide
Also known as Triple-G
An investigational triple hormone agonist (GLP-1 + GIP + glucagon) showing the largest trial weight loss yet.
Status as of 2026-07 · reclassification ≠ FDA approval · educational only, not medical advice.
The signal it sends
Adds glucagon-receptor activation (more energy expenditure) to the GLP-1/GIP appetite effect.
Benefits & effects studied
- ~24% weight loss at 48 weeks in Phase II
- Reduced liver fat
- Strong metabolic improvements
Research state
Phase III ongoing; not yet approved. Among the most-watched metabolic drugs of 2026.
Dosing & pharmacokinetics
Weekly subcutaneous injection (trial protocols). Half-life: ~6 days (once-weekly).
Dosing information is educational only. Retatrutide decisions belong with a licensed clinician — Jevity does not recommend or supply dosing.
History & discovery
First described early 2020s by Eli Lilly Origin: Developed by Eli Lilly (as LY3437943) by extending the incretin-agonist concept into a single molecule that activates three metabolic hormone receptors at once, for obesity and diabetes; currently in Phase 3 trials..
Molecular structure
A synthetic 39-amino-acid peptide built on a GIP backbone with non-coded residues and a C20 fatty diacid side chain, acting as a triple GLP-1/GIP/glucagon receptor agonist.
Frequently asked questions
Is Retatrutide FDA-approved?
Investigational — Phase 3 trials (not approved) On Jevity's evidence scale, Retatrutide is graded "In human trials". Reclassification for compounding is not the same as FDA approval.
What is Retatrutide used for?
An investigational triple hormone agonist (GLP-1 + GIP + glucagon) showing the largest trial weight loss yet. Adds glucagon-receptor activation (more energy expenditure) to the GLP-1/GIP appetite effect. Studied effects include: ~24% weight loss at 48 weeks in Phase II; Reduced liver fat; Strong metabolic improvements. This is educational information, not a recommendation to use it.
Is Retatrutide legal in the UAE?
UAE / DHA status: Not available — investigational
Is Retatrutide banned in sport?
WADA status: Not prohibited
What is Retatrutide's Jevity Score?
Retatrutide has a Jevity Score of 58/100 — a proprietary composite of evidence strength (7/10), regulatory clarity (5/10) and supply verifiability (4/10). It reflects how established and legitimate the compound is, not a recommendation.
Related metabolic & weight peptides
Educational information only — not medical advice, a diagnosis, or a recommendation to use any substance or therapy. Regulatory status changes; verify current rules and any personal decision with a licensed clinician. Jevity is operated by Upcapital Global FZCO, Dubai, UAE.